AbCellera Biologics Inc. (ABCL) financial statements (2022 and earlier)

Company profile

Business Address 2215 YUKON STREET
VANCOUVER, BC V5Y 0A1
State of Incorp. BC
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments476
Cash and cash equivalents476
Receivables14
Other current assets21
Other undisclosed current assets418
Total current assets:930
Noncurrent Assets
Property, plant and equipment112
Long-term investments and receivables50
Long-term investments50
Intangible assets, net (including goodwill)196
Goodwill48
Intangible assets, net (excluding goodwill)148
Other noncurrent assets31
Total noncurrent assets:389
TOTAL ASSETS:1,319
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:15
Accrued liabilities23
Employee-related liabilities4
Taxes payable36
Other undisclosed accounts payable and accrued liabilities(47)
Deferred revenue8
Business combination, contingent consideration, liability23
Other undisclosed current liabilities75
Total current liabilities:121
Noncurrent Liabilities
Long-term debt and lease obligation36
Operating lease, liability36
Liabilities, other than long-term debt75
Deferred income tax liabilities37
Other liabilities2
Business combination, contingent consideration, liability36
Other undisclosed noncurrent liabilities61
Total noncurrent liabilities:172
Total liabilities:293
Stockholders' equity
Stockholders' equity attributable to parent1,026
Common stock722
Additional paid in capital35
Accumulated other comprehensive income0
Retained earnings268
Total stockholders' equity:1,026
TOTAL LIABILITIES AND EQUITY:1,319

Income statement (P&L) ($ in millions)

12/31/2021
Revenues375
Gross profit:375
Operating expenses(171)
Operating income:204
Nonoperating income15
Investment income, nonoperating3
Other nonoperating expense(5)
Income from continuing operations before income taxes:219
Income tax expense(66)
Net income available to common stockholders, diluted:153

Comprehensive Income ($ in millions)

12/31/2021
Net income:153
Comprehensive income:153
Other undisclosed comprehensive income, net of tax, attributable to parent0
Comprehensive income, net of tax, attributable to parent:154

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: